Respiratory Research

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Retrieved on: 
Wednesday, April 3, 2024
Research, Extracellular matrix, B cell, ECM, Regeneration, Idiopathic pulmonary fibrosis, AT2, Inflammation, Lung, SWAP, Respiratory Research, Macrophage, IPF, Pulmonary fibrosis, Fibrosis, Therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today publication of data in Respiratory Research highlighting the potential for Surrozen’s Wnt mimetic technologies to treat serious lung diseases like idiopathic pulmonary fibrosis (IPF) https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-0.... The results observed with systemic administration of Surrozen’s Wnt mimetic antibody in an acute bleomycin model of pulmonary fibrosis demonstrate a Wnt pathway mediated decrease in inflammation and fibrosis and improvement in lung function.

Key Points: 
  • The results observed with systemic administration of Surrozen’s Wnt mimetic antibody in an acute bleomycin model of pulmonary fibrosis demonstrate a Wnt pathway mediated decrease in inflammation and fibrosis and improvement in lung function.
  • Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by areas of myofibroblast accumulation and extracellular matrix (ECM) deposition, disruption of alveolar architecture, and restricted lung physiology.
  • In pulmonary fibrosis, multiple cell types may need to be targeted to provide a regenerative environment facilitating repair.
  • “This work published in Respiratory Research represents a breakthrough in understanding the role of the Wnt pathway in lung fibrosis and the potential for Wnt mimetics to reduce fibrosis and improve lung function.”

bioAffinity Technologies Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Patent, Use, Compensator (control theory), Journal of Visualized Experiments, Marketing, Respiratory Research, Clinical trial, Lung cancer, Receiver operating characteristic, Pulmonology, BIAF, Research, Lung, IPO, Flow cytometry, Treating, Patient, Physician, European, CFO, FDA, Therapy, Medical imaging, Medical device, Pharmaceutical industry, ROC

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three months ended March 31, 2023.

Key Points: 
  • bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three months ended March 31, 2023.
  • Highlights from the first quarter of 2023 and subsequent weeks included:
    Appointed Michael Dougherty as Chief Financial Officer.
  • Research and development expenses were $370,000 for the first quarter of 2023, compared with $280,000 for the comparable period in 2022.
  • Clinical development expenses were $20,000 for the first quarter of 2023, compared with $53,000 for the first quarter of 2022.

bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Friday, March 31, 2023
Science, Biotechnology, Research, Oncology, Health, Medical Devices, Clinical Trials, Other Health, Sputum, COPD, Survival rate, Exercise, IPO, LDT, American Lung Association, Physician, Communication, Survival, Food and Drug Administration, Respiratory Research, Cancer, Lung cancer, Receiver operating characteristic, Medicine, BIAF, Lung, Sale, Chronic obstructive pulmonary disease, Patient, Patent, Machine learning, Flow cytometry, Laboratory developed test, United Kingdom, Diagnosis, Porphyrin, Therapy, National Board of Medical Examiners, Food, Biopsy, Medical imaging, Security (finance), Pharmaceutical industry, Video game, Cryptocurrency, ROC

Revenue for the fourth quarter of 2022 was approximately $2,500, compared with no revenue for the prior-year period.

Key Points: 
  • Revenue for the fourth quarter of 2022 was approximately $2,500, compared with no revenue for the prior-year period.
  • Research and development expenses were $429,000 for the fourth quarter of 2022, compared with $318,000 for the comparable period in 2021.
  • General and administrative expenses were $1.2 million for the fourth quarter of 2022, compared with $341,000 for the comparable period in 2021.
  • bioAffinity Technologies believes that its available cash will be sufficient to fund planned operations for at least the next 12 months.